Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients

Human Psychopharmacology

Volumn 19, Issue 5, 2004, Pages 293-298

  Vandel, P ^a   Haffen, E ^a   Nezelof, S ^a   Broly, F ^b   Kantelip, J P ^a   Sechter, D ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clomipramine; CYP2D6; Fluoxetine; Phenotype

Indexed keywords

ALPRAZOLAM; BROMAZEPAM; CITALOPRAM; CLOMIPRAMINE; CLORAZEPATE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; FLUOXETINE; OXAZEPAM; PRAZEPAM; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACCOMMODATION; ADULT; AGED; ARTICLE; CAUCASIAN; CONSTIPATION; CONTROLLED STUDY; DRUG METABOLISM; DYSTHYMIA; EYE DISEASE; FEMALE; GENOTYPE; HETEROZYGOSITY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC CAPACITY; ORTHOSTATIC HYPOTENSION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREMOR; XEROSTOMIA;

EID: 4243061841     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.598     Document Type: Article

References (34)

1. Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. 2000. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40: 58-66.
2. Anderson T, Miners JO, Veronese ME, Birkett DJ. 1994. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38: 131-137.
3. Arthur H, Dahl ML, Siwers B, Sjöqvist F. 1995. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 15: 211-216.
4. Ball SE, Ahern D, Scatina J, Kao J. 1997. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br J Clin Pharmacol 43: 619-626.
5. Baumann P. 1986. Pharmacogénétique du métabolisme des antidépresseurs. Test à la débrisoquine. Encephale 12: 143-148.
6. Baumann P, Eap CB. 2001. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol 16(S2): S85-S92.
7. Bergström RF, Peyton AL, Lemberger L. 1992. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 5: 239-248.
8. Bertilsson L, Dahl ML. 1996. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223.
9. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA. 1995. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenet 5: 373-384.
10. Brosen K. 1993. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 71: 1002-1009.
11. Brosen K, Gram F. 1989. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537-547.
12. Brosen K, Skjelbo E. 1991. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 32: 136-137.
13. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. 1996. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcome in psychiatry. Clin Pharmacol Ther 60: 522-534.
14. Cholerton S, Daly AK, Idle JR. 1992. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434-439.
15. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. 1992. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265.
16. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle J. 1991. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1: 33-41.
17. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenet 6: 193-201.
18. Derenne F, Joanne C, Vandel S, Bertschy G, Volmat R, Bechtel P. 1989. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 36: 53-58.
19. Eichelbaum M, Gross AS. 1990. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 46: 377-394.
20. Gonzalez F, Skoda RC, Kimura S, Umeno M, Zanger U, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 31: 442-446.
21. Hindmarch I. 2001. The enantiomer debate: current status and future directions. Hum Psychopharmacol 16(S2): S101-S104.
22. Küpfer A, Schmid B, Preisig R, Pfaff G. 1984. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 2: 517-518.
23. Leon (de) J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. 1998. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 155: 1278-1280.
24. Nielsen KK, Flinois JP, Beaune P, Brosen K. 1996. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277: 1659-1664.
25. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. 1993. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401-409.
26. Perault MC, Bouquet S, Bertschy G, Vandel S, Chakroun R, Guibert S, Vandel B. 1991. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment. Therapie 46: 1-3.
27. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. 2004. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 19(1): 17-23.
28. Schmid B, Bircher J, Preisig R, Kupfer A. 1985. Polymorphic dextromethorphan metabolism: co-segregation of oxydative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618-624.
29. Spina E, Ancione M, Di Rossa AE, Meduri M, Caputi AP. 1992. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42: 347-348.
30. Spina E, Campo GM, Avenoso A, et al. 1994. CYP2D6-related oxidation polymorphism in Italy. Pharmacol Res 29: 281-289.
31. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. 1997. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51: 395-398.
32. Tanaka E. 1998. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome, P450 enzymes. J Clin Pharm Ther 23: 403-416.
33. Vandel S, Bertschy G, François T, Vandel B, Sechter D, Bizouard P. 1992. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25: 202-207.
34. Vandel P, Haffen H, Vandel S, Bonin B, Nezelof S, Sechter D, Broly F, Bizouard P, Dalery J. 1999. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 55: 659-665.